TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 320929

Group type: EXPERIMENTAL
Intervention: Hyperimmune globulin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 30
Study: 31239328

Group type: EXPERIMENTAL
Intervention: Thrombectomy for anterior AIS in patients aged <80 years
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thrombectomy for anterior AIS in patients aged ≥80 years
Number of subjects: 20
Study: 30730866

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium (40 mg) combined with TAP block (150 mg of 0.375% ropivacaine with 5 mg dexamethasone)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium combined with TAP block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (40 mg) without TAP block
Number of subjects: 100
Study: 28787431

Group type: EXPERIMENTAL
Intervention: Left side TIVAD implantation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Right side TIVAD implantation
Number of subjects: 240
Study: 25504506

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide transarterial chemoembolization and intravenous administration of arsenic trioxide
Number of subjects: 139

Group type: COMPARATOR
Intervention: Arsenic trioxide transarterial chemoembolization
Number of subjects: 139
Study: 22865778

Group type: EXPERIMENTAL
Intervention: Stroma-high (>50%)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Stroma-low (≤50%)
Number of subjects: 710
Study: 20921922

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg intravenously) administered at anesthetic induction
Number of subjects: 38
Study: 19318461

Group type: EXPERIMENTAL
Intervention: Increasing anticholinergic load from symptom-specific medications
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Increasing anticholinergic load
Number of subjects: 304
Study: 16505800

Group type: EXPERIMENTAL
Intervention: Bio-adhesive 0.2% chlorhexidine gel applied once after extraction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no chlorhexidine gel)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental group (chlorhexidine gel)
Number of subjects: 30
Study: 14959876

Group type: EXPERIMENTAL
Intervention: Multimedia tutorial
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 11414873

Group type: EXPERIMENTAL
Intervention: Staff-implemented treatments designed to experimentally increase intentional communication ability
Number of subjects: 58
Study: 9072480

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Diabetics on CAPD
Number of subjects: 166

Group type: COMPARATOR
Intervention: Non-diabetics on CAPD
Number of subjects: 166
Study: 8302763

Group type: EXPERIMENTAL
Intervention: 0.3 mg oral dose of fadrozole hydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.0 mg oral dose of fadrozole hydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.0 mg oral dose of fadrozole hydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride (all doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride
Number of subjects: 18
Study: 2896796

Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate with sodium cromoglycate eye drops (Beconase and Opticrom)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (Depo‐Medrone)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Astemizole (Hismanal)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Terfenadine (Triludan)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Mequitazine (Primalan)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (Piriton)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Sodium cromoglycate nasal insufflation with xylometazoline/antazoline eye drops (Rynacrom and Otrivine‐Antistin)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Azatadine maleate (Optimine)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Dimethothiazine (Banistyl)
Number of subjects: 640
Study: 31550915

Group type: EXPERIMENTAL
Intervention: 300,000 IU of intramuscular vitamin D
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27775998

Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone at induction and 250 mg methylprednisolone before cardiopulmonary bypass
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 26247968

Group type: EXPERIMENTAL
Intervention: Chia oil (16 mL daily) from the third trimester of pregnancy until the first six months of nursing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with normal feeding
Number of subjects: 40
Study: 23438946

Group type: EXPERIMENTAL
Intervention: Tacrolimus (5 mg) in CYP3A5 expressers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study: 21527202

Group type: EXPERIMENTAL
Intervention: 1% testosterone propionate ointment twice daily for 30 days before surgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 26
Study: 19623047

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Blood glucose levels < or =1.2 mmol/L
Number of subjects: 523
Study: 16418786

Group type: EXPERIMENTAL
Intervention: Oral alendronate (10 mg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 15054349

Group type: EXPERIMENTAL
Intervention: 8.4 g/day larch arabinogalactan (n=18)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 8.4 g/day tamarack arabinogalactan (n=19)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo of rice starch (n=17)
Number of subjects: 74
Study: 11198705

Group type: EXPERIMENTAL
Intervention: High dose of intramuscular thiamin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Other doses of intramuscular thiamin
Number of subjects: 107
Study: 10211007

Group type: EXPERIMENTAL
Intervention: 1 MAC (1.1%) of isoflurane in oxygen for 30 min followed by 1 MAC (2.1%) of sevoflurane in oxygen for 30 min
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 MAC (2.1%) of sevoflurane in oxygen for 30 min followed by 1 MAC (1.1%) of isoflurane in oxygen for 30 min
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia in subgroup with pulmonary artery catheters (n = 12)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia in subgroup with pulmonary artery catheters (n = 12)
Number of subjects: 28
Study: 8166187

Group type: EXPERIMENTAL
Intervention: Intensified management
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Nondiabetic control
Number of subjects: 1145
Study: 3139325

Group type: EXPERIMENTAL
Intervention: 6,000 units pro‐urokinase i.c. (group H)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 3,000 units pro‐urokinase i.c. (group L)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 960,000 IU urokinase i.c. (group U)
Number of subjects: 144
Study: 29044725

Group type: EXPERIMENTAL
Intervention: Teriparatide therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27487573

Group type: EXPERIMENTAL
Intervention: Dynamic Psychotherapy (DT)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 237
Study: 24743460

Group type: EXPERIMENTAL
Intervention: Home-based sensorimotor training program (45 mins, 5 days/week for 8 weeks)
Number of subjects: 12
Study: 24473581

Group type: EXPERIMENTAL
Intervention: Self-stigma reduction programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher global functioning, better readiness for action, and lower self-esteem decrement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesser psychiatric symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-stigmatisation
Number of subjects: 0
Study: 20602260

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 18784609

Group type: EXPERIMENTAL
Intervention: Maca (3.5 g/day for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 6 weeks)
Number of subjects: 14
Study: 16651830

Group type: EXPERIMENTAL
Intervention: Test drug (T) - oral desmopressin acetate 400 mug
Number of subjects: 60
Study: 12021946

Group type: EXPERIMENTAL
Intervention: AR-R15896AR
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 9683118

Group type: EXPERIMENTAL
Intervention: Investigational interleukin-2 (IL-2) therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not receiving IL-2)
Number of subjects: 50
Study: 9160569

Group type: EXPERIMENTAL
Intervention: Brofaromine (a combined MAO‐A inhibitor/5‐HT transport inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2742416

Group type: EXPERIMENTAL
Intervention: Brachytherapy (delayed loading of radioactive sources after 5 days post-operation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No radiation (control group)
Number of subjects: 50
Study: 4202265

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 229

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 229
Study: 31134657

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg, twice daily for 5 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 26957489

Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (PEM 0.5%)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (PEM 1%)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (PEM 0.5% and 1%)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 24045099

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (3.4±1.1mL/d) for 3 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: No fish oil (−FO)
Number of subjects: 83
Study: 21403974

Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. program participants
Number of subjects: 3797

Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. program participants who regarded the program as helpful
Number of subjects: 3797
Study: 19910804

Group type: EXPERIMENTAL
Intervention: Leg press exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chest press exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lat pull down exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 30
Study: 17989382

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study: 15553345

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of an information booklet on postnatal depression and an audiotape of one woman's journey through clinical postnatal depression.
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 184
Study: 11498312

Group type: EXPERIMENTAL
Intervention: PGE(1) at a rate of 0.02 microg/kg/min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline at a rate of 2 mL/min (control group)
Number of subjects: 14
Study: 9921700

Group type: EXPERIMENTAL
Intervention: SSRI plus buspirone
Number of subjects: 119

Group type: COMPARATOR
Intervention: SSRI plus placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: SSRI plus buspirone (open-label poststudy treatment)
Number of subjects: 119
Study: 7519866

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moclobemide 600 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moclobemide (various doses)
Number of subjects: 8
Study: 2667326

Group type: EXPERIMENTAL
Intervention: Interferon alternating with chemotherapy (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chemotherapy only (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interferon alternating with chemotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both arms (Interferon alternating with chemotherapy and Chemotherapy only)
Number of subjects: 36
Study: 171057

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy followed by surgery (290 patients)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Immediate surgery (278 patients)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Surgery after radiotherapy (78 patients)
Number of subjects: 703

Group type: COMPARATOR
Intervention: No surgery (74 patients)
Number of subjects: 703
Study: 31221891

Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for detection of paediatric SIRS; specific dosage and duration not mentioned.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine clinical care decisions; specific dosage and duration not mentioned.
Number of subjects: 300
Study: 28576452

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg once a day for 12 weeks
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo once a day for 12 weeks
Number of subjects: 1100
Study: 26323728

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5μg/kg/10min infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous saline infusion (Control Group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23145864

Group type: EXPERIMENTAL
Intervention: Lacrimal probing and irrigation with adjunctive mitomycin-C (1 mL of 0.2 mg/mL, once)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Only probing (control)
Number of subjects: 40
Study: 21605317

Group type: EXPERIMENTAL
Intervention: Race × physical health (BMI as dependent variable)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Race × percentage of dietary fat (total dietary kilocalories as dependent variable)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Race × median income (exercise minutes per week as dependent variable)
Number of subjects: 451
Study: 19635606

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha2b (IFN) as an adjuvant to HBV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: HBV vaccine alone
Number of subjects: 0
Study: 17111013

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1 g.kg body mass(‐1))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (non-caloric drink)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16900304

Group type: EXPERIMENTAL
Intervention: Integrated treatment (ACT, social skills training, and family intervention)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study: 14620895

Group type: EXPERIMENTAL
Intervention: Echogenic polymer-coated needle
Number of subjects: 61

Group type: COMPARATOR
Intervention: Untreated needle
Number of subjects: 61

Group type: COMPARATOR
Intervention: Teflon-coated needle
Number of subjects: 61

Group type: COMPARATOR
Intervention: Etched tip needle
Number of subjects: 61
Study: 11329095

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Fosinopril 40 mg
Number of subjects: 179

Group type: COMPARATOR
Intervention: Fosinopril 1 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg and 40 mg)
Number of subjects: 179
Study: 7753432

Group type: EXPERIMENTAL
Intervention: Plasmatic beta 2‐microglobulin measurement in group A (microalbuminuria)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Plasmatic beta 2‐microglobulin measurement in group B (normal albuminuria)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Plasmatic beta 2‐microglobulin measurement in group C (healthy control)
Number of subjects: 62
Study: 2191878

Group type: EXPERIMENTAL
Intervention: 1.0 g acetylsalicylic acid (ASA) per day, starting day two prior to surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group without antiplatelet medication
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1.0 g acetylsalicylic acid (ASA) in patients with signs of progression in histopathological examination
Number of subjects: 66

Group type: COMPARATOR
Intervention: No ASA in patients without signs of cellular infiltration
Number of subjects: 66
Study: 76397

Group type: EXPERIMENTAL
Intervention: Zinc sulphate tablets, 0.6 g daily for 4 weeks
Number of subjects: 26
Study: 30781781

Group type: EXPERIMENTAL
Intervention: Dietary counseling (Intervention Group)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Routine counseling (Control Group)
Number of subjects: 433
Study: 28335767

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored physical activity intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard information group (control)
Number of subjects: 77
Study: 25251189

Group type: EXPERIMENTAL
Intervention: High COHb (≥4 g·dl(‐1))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low COHb (≤3 g·dl(‐1))
Number of subjects: 100
Study: 22584071

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Foster care (by age 2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Foster care (by age 1; 3)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 105
Study: 21745769

Group type: EXPERIMENTAL
Intervention: Products containing sodium hypochlorite, ammonia, and triclosan used in the kitchen and bathroom for one month.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual practices for domestic cleaning (Control group).
Number of subjects: 32
Study: 19513845

Group type: EXPERIMENTAL
Intervention: Booster intervention (SAFEChildren II)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Initial intervention only (SAFEChildren I)
Number of subjects: 196
Study: 16409323

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + Hybrid technique
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + NiTi rotary technique (Hero 642)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + Hybrid technique
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + NiTi rotary technique (Hero 642)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + Hybrid technique
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl + NiTi rotary technique (Hero 642)
Number of subjects: 180

Group type: COMPARATOR
Intervention: sterile saline solution + Hybrid technique
Number of subjects: 180

Group type: COMPARATOR
Intervention: sterile saline solution + NiTi rotary technique 4 mm shorter than the apex
Number of subjects: 180

Group type: COMPARATOR
Intervention: sterile saline solution + NiTi rotary technique (Hero 642)
Number of subjects: 180
Study: 15319024

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 11122095

Group type: EXPERIMENTAL
Intervention: Primary care anticoagulation management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional hospital care-based provision
Number of subjects: 0
Study: 9489432

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NED) 8mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8384073

Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy (vincristine during RT, followed by vincristine, cisplatin, and lomustine for eight cycles every 6 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy
Number of subjects: 10
Study: 2936841

Group type: EXPERIMENTAL
Intervention: Written instructional booklet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral instruction from physician and clinical nurse specialist
Number of subjects: 0
Study: 30039736

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 105
Study: 29115703

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT) at 200 mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 25709987

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg iv 2 minutes before induction of anesthesia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral gabapentin 300 mg 1 hour before anesthesia
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 23683569

Group type: EXPERIMENTAL
Intervention: Phoxilium
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hemosol-B0
Number of subjects: 15
Study: 21415104

Group type: EXPERIMENTAL
Intervention: Selenium (500 μg/day)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Glutamine (20.2 g/day)
Number of subjects: 502
Study: 19615135

Group type: COMPARATOR
Intervention: Fluid resuscitation (group A)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration and fluid resuscitation (group B)
Number of subjects: 89
Study: 16759540

Group type: EXPERIMENTAL
Intervention: Diagnostic model using serum protein fingerprint and support vector machine (SVM) with 3 biomarkers
Number of subjects: 81
Study: 12752541

Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures (IOD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional dentures (CD)
Number of subjects: 60
Study: 11922148

Group type: EXPERIMENTAL
Intervention: Diet and oral hypoglycaemic drug (Daonil) therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (thirty-four apparently healthy individuals)
Number of subjects: 35
Study: 9725753

Group type: EXPERIMENTAL
Intervention: Halcion (triazolam) 0.375 mg p.o.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8036521

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX)
Number of subjects: 0